These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34709636)

  • 21. Characterization of the ectodomain of the envelope protein of dengue virus type 4: expression, membrane association, secretion and particle formation in the absence of precursor membrane protein.
    Hsieh SC; Tsai WY; Nerurkar VR; Wang WK
    PLoS One; 2014; 9(6):e100641. PubMed ID: 24950216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional importance of dengue virus maturation: infectious properties of immature virions.
    Zybert IA; van der Ende-Metselaar H; Wilschut J; Smit JM
    J Gen Virol; 2008 Dec; 89(Pt 12):3047-3051. PubMed ID: 19008392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development.
    Elong Ngono A; Shresta S
    Front Immunol; 2019; 10():1316. PubMed ID: 31244855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
    Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
    Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
    Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
    J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonstructural protein 1-specific immunoglobulin M and G antibody capture enzyme-linked immunosorbent assays in diagnosis of flaviviral infections in humans.
    Chao DY; Galula JU; Shen WF; Davis BS; Chang GJ
    J Clin Microbiol; 2015 Feb; 53(2):557-66. PubMed ID: 25502522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
    Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.
    Mareze VA; Borio CS; Bilen MF; Fleith R; Mirazo S; Mansur DS; Arbiza J; Lozano ME; Bruña-Romero O
    Appl Microbiol Biotechnol; 2016 Jan; 100(1):125-33. PubMed ID: 26386688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment and Application of Flavivirus Replicons.
    Kümmerer BM
    Adv Exp Med Biol; 2018; 1062():165-173. PubMed ID: 29845532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.
    Shukla R; Ramasamy V; Shanmugam RK; Ahuja R; Khanna N
    Front Cell Infect Microbiol; 2020; 10():572681. PubMed ID: 33194810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reciprocal Effects of Fibroblast Growth Factor Receptor Signaling on Dengue Virus Replication and Virion Production.
    Cortese M; Kumar A; Matula P; Kaderali L; Scaturro P; Erfle H; Acosta EG; Buehler S; Ruggieri A; Chatel-Chaix L; Rohr K; Bartenschlager R
    Cell Rep; 2019 May; 27(9):2579-2592.e6. PubMed ID: 31141684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
    Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
    Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The kinase inhibitor SFV785 dislocates dengue virus envelope protein from the replication complex and blocks virus assembly.
    Anwar A; Hosoya T; Leong KM; Onogi H; Okuno Y; Hiramatsu T; Koyama H; Suzuki M; Hagiwara M; Garcia-Blanco MA
    PLoS One; 2011; 6(8):e23246. PubMed ID: 21858043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties.
    Liu W; Jiang H; Zhou J; Yang X; Tang Y; Fang D; Jiang L
    Virus Genes; 2010 Feb; 40(1):53-9. PubMed ID: 19885726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The helical domains of the stem region of dengue virus envelope protein are involved in both virus assembly and entry.
    Lin SR; Zou G; Hsieh SC; Qing M; Tsai WY; Shi PY; Wang WK
    J Virol; 2011 May; 85(10):5159-71. PubMed ID: 21367896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C-terminal helical domains of dengue virus type 4 E protein affect the expression/stability of prM protein and conformation of prM and E proteins.
    Tsai WY; Hsieh SC; Lai CY; Lin HE; Nerurkar VR; Wang WK
    PLoS One; 2012; 7(12):e52600. PubMed ID: 23300717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and production of dengue virus chimeric proteins useful for developing tetravalent vaccines.
    Batista ICA; Quinan BR; Rocha Alves ÉA; Jangola STG; Oliveira ES; Colombarolli SG; Ferreira JGG; Rocha ESO; Kroon EG; de Assis RR; de Oliveira JG; Fiuza JA; Calzavara-Silva CE
    Vaccine; 2020 Feb; 38(8):2005-2015. PubMed ID: 31982262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.